ATAI Life Sciences NV
NASDAQ:ATAI
ATAI Life Sciences NV
NASDAQ:ATAI
Price:
1.91 USD
-1.55%
Market Closed
Updated:
May 15, 2024
Section:
Relative Value
The Relative Value of one
ATAI
stock under the Base Case scenario is
2.43
USD.
Compared to the current market price of 1.91 USD,
ATAI Life Sciences NV
is
Undervalued by 22%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ATAI
Relative Value
Base Case
2.43
USD
Undervaluation 22%
Valuation Multiples
Multiples Across Competitors
ATAI Competitors Multiples
ATAI Life Sciences NV Competitors
ATAI Life Sciences NV Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
317.1m USD | 1 009.9 | -7.9 | -1.2 | -1.2 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
726.1B USD | 20.2 | 118.3 | 57.9 | 65.9 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 16.6 | 45.4 | 33.9 | 37.1 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
364.3B USD | 4.3 | 9.5 | 11.7 | 15.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
325.9B USD | 5.3 | 141.3 | 35.2 | 57.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
189.8B GBP | 5 | 37.7 | 174.6 | 278.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.9B CHF | 3.4 | 11.5 | 8.8 | 12.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
179.1B CHF | 3 | 15.6 | 8.9 | 10.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
160.2B USD | 2.9 | -518.6 | 12.8 | 20.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
